Health Affairs, 25, no. 5 (2006): 1270 doi: 10.1377/hlthaff.25.5.1270 © 2006 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Related Collections Insurance Market Access To Care Business Of Health Consumer Issues Evidence-Based Medicine Insurance Coverage Pharmaceuticals Research And Technology Health Spending

Evolution & Future

PROLOGUE

Evolution And Future Of Biopharmaceuticals

Advances in genetics and genomics, including the sequencing of the human genome, have resulted in the development of new biologic drugs to treat cancer and other serious diseases. So-called targeted therapeutics are the first step in creating drugs that home in on disease without affecting healthy cells and tissues. Not surprisingly, the arrival of these drugs about a decade ago has raised lingering questions about their clinical and financial value, how they should be regulated, and whether changes in patent policy are necessary to promote innovation. Because the new biological agents are more difficult to manufacture than traditional chemically synthesized . . . [Full Text of this Article]

                      What's this?